Galectin Therapeutics to Participate in Three Investment Conferences in September

NORCROSS, Ga., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that executive management will be participating in three investment conferences in September, as follows:

  • Peter G. Traber, M.D., chief executive officer, president and chief medical officer of Galectin Therapeutics, will make a corporate presentation at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th at the St. Regis Hotel in New York City from 10:50am to 11:15am Eastern time. Management will also be holding one-on-one meetings at the conference.
  • Jim Czirr, executive chairman, will hold one-on-one meetings at the 22nd Annual BioCentury NewsMakers in the Biotech Industry Conference on September 10th at the Millennium Broadway Hotel & Conference Center in New York City.
  • Dr. Traber will make a corporate presentation at the 2015 Ladenburg Thalmann Healthcare Conference on September 29th at the Sofitel Hotel in New York City from 11:00am to 11:25am Eastern time. Management will also be holding one-on-one meetings at the conference.

The presentations by Dr. Traber at the Rodman & Renshaw and the Ladenburg Thalmann conferences will be available through webcast. To listen to the presentations, investors may visit the investor relations section of the Galectin Therapeutics website at www.galectintherapeutics.com. An archived audio of the presentations will also be available on Galectin Therapeutics' website for 90 days.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

CONTACT: Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com. LHA Kim Golodetz (212) 838-3777 kgolodetz@lhai.com

Source:Galectin Therapeutics, Inc.